2009
DOI: 10.1016/j.amjcard.2008.10.018
|View full text |Cite
|
Sign up to set email alerts
|

Closure of Atrial Septal Defect With the Amplatzer Septal Occluder in Adults

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

4
76
1
2

Year Published

2009
2009
2023
2023

Publication Types

Select...
5
4

Relationship

0
9

Authors

Journals

citations
Cited by 116 publications
(93 citation statements)
references
References 28 publications
4
76
1
2
Order By: Relevance
“…[15][16][17] This procedure is also reported as safe and effective for patients with PAH. 7-9 The benefits of the transcatheter procedure over standard cardiac surgery are avoidance of thoracotomy and cardiopulmonary bypass, and reduced requirement for blood products.…”
Section: Discussionmentioning
confidence: 99%
“…[15][16][17] This procedure is also reported as safe and effective for patients with PAH. 7-9 The benefits of the transcatheter procedure over standard cardiac surgery are avoidance of thoracotomy and cardiopulmonary bypass, and reduced requirement for blood products.…”
Section: Discussionmentioning
confidence: 99%
“…Nitinol containing devices for transcatheter closure of atrial septal defects (ASD) have been used worldwide over the past decade (1,2). These nitinol devices not only provided excellent results, but also made for safe and easy device implantation (1,2). Meanwhile, there are certain contraindications and limitations to this relatively popular technique that should be acknowledged.…”
Section: Introductionmentioning
confidence: 99%
“…6) Device embolization is a common and potentially fatal complication of percutaneous ASD closure, which may be a result of inadequate rim margins, improper sizing, and improper placement of the device. 1,7,8) Our patient had an aortic rim measuring 2 mm, and margins of < 5 mm may predispose the patient to early and late device embolization. 9) Surgery for retrieval of the device is a proposed treatment, but it carries additional risks including bleeding secondary to antiplatelet therapy.…”
Section: Discussionmentioning
confidence: 99%